Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633893 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
A Phase 3 study of Venous Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,711
- Enrollment target
- 20
- Study locations
NCT00633893: Completed Phase 3 study of Venous Thrombosis, sponsored by Bristol-Myers Squibb.
NCT00633893 is a Phase 3 study of Venous Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,711 participants, above the 824-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (229% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633893, a Phase 3 study of Venous Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,711 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
Primary Outcome
VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participa
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
Study Locations (20)
California
- Beaver Medical Group - Banning
- Scripps Clinic/Scripps Health And Green Hospital - La Jolla
- Healthcare Partners Medical Group - Los Angeles
- Mission Internal Medical Group - Mission Viejo
- Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group - Palm Springs
- Indus Clinical Research Institute, Inc. - Pomona
- Kaiser Permanente Medical Center - San Francisco
- Stanford University Medical Center - Stanford
- Harbor Ucla Medical Center - Torrance
- Progressive Clinical Research - Vista
Florida
- Bay Pines Va Healthcare Systems - Bay Pines
- Research Alliance, Inc. - Clearwater
- St. Francis Sleep Allergy & Lung Institute - Clearwater
Arizona
- Cardiovascular Consultants, Ltd. - Phoenix
- Robert J. Bloomberg, Md, Pc - Tempe
Colorado
- Rocky Mountain Internal Medicine - Aurora
- New West Physicians - Golden
Alabama
- Alabama Clinical Therapeutics, Llc - Birmingham
Arkansas
- Fort Smith Lung Center - Fort Smith
Delaware
- Alfieri Cardiology - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,711 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT00633893 record still lists
NCT00633893 is an interventional study that assigns participants to a tested intervention. Its 2,711 participants enrollment target places it among the larger protocols in the corpus, above the 824-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (229% higher).
The record links to 1 condition, with Venous Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633893 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00633893 about?
NCT00633893 is a clinical study titled "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism". The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
What is the current status of trial NCT00633893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,711 participants. The study started on 2008-05. Estimated completion is 2012-08.
What conditions does trial NCT00633893 study?
This clinical trial studies the following conditions: Venous Thrombosis.
What interventions are being tested in trial NCT00633893?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00633893?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633893 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00633893's enrollment target sits among peer trials
2,711 2nd of 9 the highest of 9 other Venous Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
COMPLETED · Phase 3
-
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
COMPLETED · Phase 3
-
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
COMPLETED · Phase 3
-
JETi Lower Extremity Venous Thrombosis
ACTIVE NOT RECRUITING
-
Registry of AngioJet Use in the Peripheral Vascular System
COMPLETED
-
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia